Wellgistics Health, Inc. Secures Preferred Pricing for Insurance Eligibility & Benefits Verification, Accelerating PharmacyChain™ Adoption

Key Highlights for Investors

• Major Strategic Win: Wellgistics Health, Inc. (NASDAQ: WGRX) announced it has secured contractual rights to preferred pricing for medical insurance eligibility and benefits verification (EBV) services. This critical capability is being immediately made available to providers, partners, and the Wellgistics Pharmacy Network.
• Immediate Revenue Opportunity: The preferred pricing access enables Wellgistics to open a new revenue stream with its core customer base and partners, supporting the broader rollout of its PharmacyChain™ smart contracts platform and its GLP-1 and Forzet™ weight loss offerings.
• Market Growth: The EBV market is projected to grow from \$2.39 billion in 2025 to \$3 billion by 2030, driven by increasing healthcare billing complexity, rising insurance claim denial rates, expansion of digital health records, and a growing need for revenue cycle optimization.
• Integration with AI and Blockchain: Wellgistics is integrating EBV services with its proprietary EinsteinRx™ AI platform and its patented blockchain-enabled PharmacyChain™ smart contracts system, positioning the company at the forefront of digital pharmacy infrastructure.

Details Investors Need to Know

The addition of EBV capabilities is a critical technology step for PharmacyChain™, as insurance eligibility and benefits verification is essential for providers and pharmacies to determine if a medical product or service is covered under a patient’s insurance and to understand provider reimbursement rates as well as patient out-of-pocket expenses.

Each time EBV information is requested, a fee is incurred. With Wellgistics’ preferred pricing, these costs are now lower for its network, which not only enhances the value proposition to customers but also strengthens Wellgistics’ competitive position and can improve margins as the company rolls out important new offerings such as GLP-1 and Forzet™ weight loss therapies.

According to Prashant Patel, RPh, President & Interim-CEO, this development is expected to create a meaningful new revenue stream beginning in Q2 2026, while also reducing corporate pharmacy costs. This pricing certainty also enables Wellgistics to advance its software development for PharmacyChain™, which the company describes as the “health technology railroad” for the serialization and tracking of drug distribution from manufacturer to patient.

The company’s integrated platform now connects over 6,500 pharmacies and 200+ manufacturers, offering a full suite of services from wholesale distribution to digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. This comprehensive approach is designed to restore access, transparency, and trust in the U.S. prescription drug market, especially for independent pharmacies.

Potential Share Price Impact and Investor Considerations

• Rapid Expansion of Service Offerings: The ability to offer preferred pricing on EBV services immediately and integrate them into PharmacyChain™ later this year can accelerate adoption of Wellgistics’ core product, driving top and bottom-line growth.
• First-Mover Advantage: Early access to preferred pricing can help Wellgistics lock in customers and partners, potentially increasing market share ahead of competitors as the EBV market expands.
• Long-Term Market Tailwinds: The underlying EBV market is forecast to grow steadily over the next five years, supported by industry trends such as increasing healthcare complexity and digitalization, all of which favor Wellgistics’ technology stack.
• Forward-Looking Risks: Investors should note Wellgistics’ forward-looking statements regarding the commercialization and adoption of its products and services. Risks include the pace of market acceptance, regulatory and compliance challenges, competitive pressures, and execution risks related to technology integration and network expansion.

Contact and Further Information

Interested parties may contact Wellgistics at [email protected]. More information is available at www.wellgisticshealth.com.

Disclaimer

This article contains forward-looking statements that involve risks and uncertainties which could cause actual results to differ materially. These statements reflect current expectations and are not guarantees of future performance. Investors are advised to review all company filings with the U.S. Securities and Exchange Commission and to conduct their own due diligence before making investment decisions. This article is for informational purposes only and does not constitute investment advice.

View Wellgistics Health, Inc. Historical chart here